Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Colorectal Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Polycystic Ovary Syndrome 1Neoplasm Metastasis 1Insulin Resistance 1Hyperandrogenism 1Glucose Intolerance 1Endometrial Neoplasms 1Clear-cell metastatic renal cell carcinoma 1Carcinoma, Renal Cell 1Carcinoma 1Anovulation 1Anastomotic Leak 1Adenomatous Polyposis Coli 1

Interventions

Nivolumab 14Ipilimumab 11Specimen Handling 9CTLA-4 Antigen 7pembrolizumab 6cabozantinib 6Magnetic Resonance Spectroscopy 6Sunitinib 5Axitinib 5pazopanib 4Biopsy 4Radiosurgery 3lenvatinib 2fludarabine 2Everolimus 2tivozanib 1sodium-iodide symporter 1sitravatinib 1belzutifan 1atezolizumab 1aldesleukin 1Zoledronic Acid 1Selenomethionine 1Radiotherapy 1Radiopharmaceuticals 1Pluvicto 1Nephrectomy 1Metastasectomy 1LY2510924 1Inulin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Clear-cell metastatic renal cell carcinoma × Inulin × Clear all
NCT06866262 2025-09-09

Inulin Gel in Combination With Ipilimumab and Nivolumab for the Treatment of Metastatic or Locally Advanced Kidney Cell Cancer, ICON Trial

University of Michigan Rogel Cancer Center

Phase 1/2 Recruiting
55 enrolled
Genitourinary

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡